Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Enfortumab Vedotin in High-Grade Urothelial Carcinoma of the Upper Urinary Tract
NCT05868265Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2023
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enfortumab vedotin in urothelial carcinoma (UC), sponsored by Memorial Sloan Kettering Cancer Center. Started Jun 2023; status: active, not recruiting.
02
Drugs
enfortumab vedotin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05868265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05868265.